nodes	percent_of_prediction	percent_of_DWPC	metapath
Betamethasone—ABCB1—Mitoxantrone—lymphatic system cancer	0.073	0.206	CbGbCtD
Betamethasone—CYP3A4—Cytarabine—lymphatic system cancer	0.0635	0.18	CbGbCtD
Betamethasone—CYP3A4—Teniposide—lymphatic system cancer	0.0626	0.177	CbGbCtD
Betamethasone—ABCB1—Vincristine—lymphatic system cancer	0.0503	0.142	CbGbCtD
Betamethasone—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0438	0.124	CbGbCtD
Betamethasone—ABCB1—Methotrexate—lymphatic system cancer	0.0304	0.086	CbGbCtD
Betamethasone—CYP3A4—Vincristine—lymphatic system cancer	0.0301	0.0851	CbGbCtD
Betamethasone—Haemorrhage—Bleomycin—lymphatic system cancer	0.00137	0.00212	CcSEcCtD
Betamethasone—Discomfort—Fludarabine—lymphatic system cancer	0.00137	0.00212	CcSEcCtD
Betamethasone—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00136	0.0021	CcSEcCtD
Betamethasone—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00135	0.00209	CcSEcCtD
Betamethasone—Petechiae—Methotrexate—lymphatic system cancer	0.00134	0.00208	CcSEcCtD
Betamethasone—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00133	0.00206	CcSEcCtD
Betamethasone—Oedema—Fludarabine—lymphatic system cancer	0.00133	0.00206	CcSEcCtD
Betamethasone—Infection—Fludarabine—lymphatic system cancer	0.00132	0.00204	CcSEcCtD
Betamethasone—Decreased appetite—Teniposide—lymphatic system cancer	0.00132	0.00204	CcSEcCtD
Betamethasone—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00131	0.00202	CcSEcCtD
Betamethasone—Vomiting—Mechlorethamine—lymphatic system cancer	0.0013	0.00202	CcSEcCtD
Betamethasone—Nervous system disorder—Fludarabine—lymphatic system cancer	0.0013	0.00202	CcSEcCtD
Betamethasone—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.0013	0.00201	CcSEcCtD
Betamethasone—Rash—Mechlorethamine—lymphatic system cancer	0.00129	0.002	CcSEcCtD
Betamethasone—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00129	0.002	CcSEcCtD
Betamethasone—Weight decreased—Vincristine—lymphatic system cancer	0.00129	0.002	CcSEcCtD
Betamethasone—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00129	0.00199	CcSEcCtD
Betamethasone—Anorexia—Fludarabine—lymphatic system cancer	0.00127	0.00196	CcSEcCtD
Betamethasone—Extravasation—Methotrexate—lymphatic system cancer	0.00127	0.00196	CcSEcCtD
Betamethasone—Weight increased—Mitoxantrone—lymphatic system cancer	0.00127	0.00196	CcSEcCtD
Betamethasone—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00126	0.00195	CcSEcCtD
Betamethasone—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00126	0.00194	CcSEcCtD
Betamethasone—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00126	0.00194	CcSEcCtD
Betamethasone—Myocardial infarction—Vincristine—lymphatic system cancer	0.00125	0.00193	CcSEcCtD
Betamethasone—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00125	0.00193	CcSEcCtD
Betamethasone—Feeling abnormal—Teniposide—lymphatic system cancer	0.00125	0.00193	CcSEcCtD
Betamethasone—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00124	0.00191	CcSEcCtD
Betamethasone—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00122	0.00189	CcSEcCtD
Betamethasone—Nausea—Mechlorethamine—lymphatic system cancer	0.00122	0.00189	CcSEcCtD
Betamethasone—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00122	0.00188	CcSEcCtD
Betamethasone—Alopecia—Bleomycin—lymphatic system cancer	0.00121	0.00188	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00121	0.00187	CcSEcCtD
Betamethasone—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00121	0.00187	CcSEcCtD
Betamethasone—Haemoglobin—Carmustine—lymphatic system cancer	0.0012	0.00186	CcSEcCtD
Betamethasone—Urticaria—Teniposide—lymphatic system cancer	0.0012	0.00186	CcSEcCtD
Betamethasone—Herpes simplex—Methotrexate—lymphatic system cancer	0.0012	0.00186	CcSEcCtD
Betamethasone—Haemorrhage—Carmustine—lymphatic system cancer	0.0012	0.00185	CcSEcCtD
Betamethasone—Body temperature increased—Teniposide—lymphatic system cancer	0.0012	0.00185	CcSEcCtD
Betamethasone—Abdominal pain—Teniposide—lymphatic system cancer	0.0012	0.00185	CcSEcCtD
Betamethasone—Erythema—Bleomycin—lymphatic system cancer	0.00119	0.00185	CcSEcCtD
Betamethasone—Paraesthesia—Fludarabine—lymphatic system cancer	0.00119	0.00185	CcSEcCtD
Betamethasone—Hallucination—Carmustine—lymphatic system cancer	0.00119	0.00184	CcSEcCtD
Betamethasone—Dyspepsia—Fludarabine—lymphatic system cancer	0.00117	0.00181	CcSEcCtD
Betamethasone—Ulcer—Methotrexate—lymphatic system cancer	0.00117	0.00181	CcSEcCtD
Betamethasone—Decreased appetite—Fludarabine—lymphatic system cancer	0.00116	0.00179	CcSEcCtD
Betamethasone—Visual impairment—Carmustine—lymphatic system cancer	0.00115	0.00179	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00115	0.00178	CcSEcCtD
Betamethasone—Fatigue—Fludarabine—lymphatic system cancer	0.00115	0.00177	CcSEcCtD
Betamethasone—Hallucination—Vincristine—lymphatic system cancer	0.00114	0.00176	CcSEcCtD
Betamethasone—Pain—Fludarabine—lymphatic system cancer	0.00114	0.00176	CcSEcCtD
Betamethasone—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00113	0.00175	CcSEcCtD
Betamethasone—Vasculitis—Methotrexate—lymphatic system cancer	0.00113	0.00175	CcSEcCtD
Betamethasone—Eye disorder—Carmustine—lymphatic system cancer	0.00112	0.00173	CcSEcCtD
Betamethasone—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00112	0.00173	CcSEcCtD
Betamethasone—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00111	0.00172	CcSEcCtD
Betamethasone—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00111	0.00172	CcSEcCtD
Betamethasone—Feeling abnormal—Fludarabine—lymphatic system cancer	0.0011	0.0017	CcSEcCtD
Betamethasone—Asthenia—Teniposide—lymphatic system cancer	0.00109	0.00168	CcSEcCtD
Betamethasone—Malaise—Bleomycin—lymphatic system cancer	0.00108	0.00167	CcSEcCtD
Betamethasone—Pruritus—Teniposide—lymphatic system cancer	0.00107	0.00166	CcSEcCtD
Betamethasone—Arrhythmia—Carmustine—lymphatic system cancer	0.00107	0.00166	CcSEcCtD
Betamethasone—Alopecia—Carmustine—lymphatic system cancer	0.00106	0.00164	CcSEcCtD
Betamethasone—Skin exfoliation—Methotrexate—lymphatic system cancer	0.00105	0.00163	CcSEcCtD
Betamethasone—Body temperature increased—Fludarabine—lymphatic system cancer	0.00105	0.00163	CcSEcCtD
Betamethasone—Erythema—Carmustine—lymphatic system cancer	0.00104	0.00161	CcSEcCtD
Betamethasone—Angiopathy—Vincristine—lymphatic system cancer	0.00104	0.00161	CcSEcCtD
Betamethasone—Diarrhoea—Teniposide—lymphatic system cancer	0.00104	0.0016	CcSEcCtD
Betamethasone—Myalgia—Bleomycin—lymphatic system cancer	0.00102	0.00157	CcSEcCtD
Betamethasone—Alopecia—Vincristine—lymphatic system cancer	0.00101	0.00156	CcSEcCtD
Betamethasone—Discomfort—Bleomycin—lymphatic system cancer	0.001	0.00155	CcSEcCtD
Betamethasone—Ecchymosis—Methotrexate—lymphatic system cancer	0.000999	0.00155	CcSEcCtD
Betamethasone—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000995	0.00154	CcSEcCtD
Betamethasone—Alopecia—Mitoxantrone—lymphatic system cancer	0.000984	0.00152	CcSEcCtD
Betamethasone—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.000983	0.00152	CcSEcCtD
Betamethasone—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000975	0.00151	CcSEcCtD
Betamethasone—Oedema—Bleomycin—lymphatic system cancer	0.000975	0.00151	CcSEcCtD
Betamethasone—Erythema—Mitoxantrone—lymphatic system cancer	0.000969	0.0015	CcSEcCtD
Betamethasone—Infection—Bleomycin—lymphatic system cancer	0.000969	0.0015	CcSEcCtD
Betamethasone—Vomiting—Teniposide—lymphatic system cancer	0.000962	0.00149	CcSEcCtD
Betamethasone—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000955	0.00148	CcSEcCtD
Betamethasone—Asthenia—Fludarabine—lymphatic system cancer	0.000954	0.00148	CcSEcCtD
Betamethasone—Rash—Teniposide—lymphatic system cancer	0.000954	0.00148	CcSEcCtD
Betamethasone—Dermatitis—Teniposide—lymphatic system cancer	0.000953	0.00147	CcSEcCtD
Betamethasone—Headache—Teniposide—lymphatic system cancer	0.000948	0.00147	CcSEcCtD
Betamethasone—Pruritus—Fludarabine—lymphatic system cancer	0.000941	0.00146	CcSEcCtD
Betamethasone—Anorexia—Bleomycin—lymphatic system cancer	0.000929	0.00144	CcSEcCtD
Betamethasone—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000926	0.00143	CcSEcCtD
Betamethasone—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000922	0.00143	CcSEcCtD
Betamethasone—Hypotension—Bleomycin—lymphatic system cancer	0.000911	0.00141	CcSEcCtD
Betamethasone—Diarrhoea—Fludarabine—lymphatic system cancer	0.00091	0.00141	CcSEcCtD
Betamethasone—Convulsion—Carmustine—lymphatic system cancer	0.000903	0.0014	CcSEcCtD
Betamethasone—Hypertension—Carmustine—lymphatic system cancer	0.0009	0.00139	CcSEcCtD
Betamethasone—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000899	0.00139	CcSEcCtD
Betamethasone—Nausea—Teniposide—lymphatic system cancer	0.000899	0.00139	CcSEcCtD
Betamethasone—Vertigo—Vincristine—lymphatic system cancer	0.000894	0.00138	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000888	0.00137	CcSEcCtD
Betamethasone—Myalgia—Carmustine—lymphatic system cancer	0.000888	0.00137	CcSEcCtD
Betamethasone—Anxiety—Carmustine—lymphatic system cancer	0.000885	0.00137	CcSEcCtD
Betamethasone—Paraesthesia—Bleomycin—lymphatic system cancer	0.000875	0.00135	CcSEcCtD
Betamethasone—Malaise—Mitoxantrone—lymphatic system cancer	0.000874	0.00135	CcSEcCtD
Betamethasone—Convulsion—Vincristine—lymphatic system cancer	0.000862	0.00133	CcSEcCtD
Betamethasone—Hypertension—Vincristine—lymphatic system cancer	0.000859	0.00133	CcSEcCtD
Betamethasone—Oedema—Carmustine—lymphatic system cancer	0.000851	0.00132	CcSEcCtD
Betamethasone—Decreased appetite—Bleomycin—lymphatic system cancer	0.000848	0.00131	CcSEcCtD
Betamethasone—Myalgia—Vincristine—lymphatic system cancer	0.000847	0.00131	CcSEcCtD
Betamethasone—Visual disturbance—Methotrexate—lymphatic system cancer	0.000846	0.00131	CcSEcCtD
Betamethasone—Infection—Carmustine—lymphatic system cancer	0.000845	0.00131	CcSEcCtD
Betamethasone—Vomiting—Fludarabine—lymphatic system cancer	0.000845	0.00131	CcSEcCtD
Betamethasone—Convulsion—Mitoxantrone—lymphatic system cancer	0.00084	0.0013	CcSEcCtD
Betamethasone—Rash—Fludarabine—lymphatic system cancer	0.000838	0.0013	CcSEcCtD
Betamethasone—Dermatitis—Fludarabine—lymphatic system cancer	0.000838	0.0013	CcSEcCtD
Betamethasone—Hypertension—Mitoxantrone—lymphatic system cancer	0.000837	0.0013	CcSEcCtD
Betamethasone—Pain—Bleomycin—lymphatic system cancer	0.000834	0.00129	CcSEcCtD
Betamethasone—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000833	0.00129	CcSEcCtD
Betamethasone—Headache—Fludarabine—lymphatic system cancer	0.000833	0.00129	CcSEcCtD
Betamethasone—Tachycardia—Carmustine—lymphatic system cancer	0.000831	0.00129	CcSEcCtD
Betamethasone—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000829	0.00128	CcSEcCtD
Betamethasone—Myalgia—Mitoxantrone—lymphatic system cancer	0.000825	0.00128	CcSEcCtD
Betamethasone—Anxiety—Mitoxantrone—lymphatic system cancer	0.000822	0.00127	CcSEcCtD
Betamethasone—Lethargy—Methotrexate—lymphatic system cancer	0.000818	0.00127	CcSEcCtD
Betamethasone—Discomfort—Mitoxantrone—lymphatic system cancer	0.000815	0.00126	CcSEcCtD
Betamethasone—Oedema—Vincristine—lymphatic system cancer	0.000812	0.00126	CcSEcCtD
Betamethasone—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000812	0.00126	CcSEcCtD
Betamethasone—Anorexia—Carmustine—lymphatic system cancer	0.000811	0.00126	CcSEcCtD
Betamethasone—Infection—Vincristine—lymphatic system cancer	0.000807	0.00125	CcSEcCtD
Betamethasone—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000803	0.00124	CcSEcCtD
Betamethasone—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000802	0.00124	CcSEcCtD
Betamethasone—Nervous system disorder—Vincristine—lymphatic system cancer	0.000797	0.00123	CcSEcCtD
Betamethasone—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000795	0.00123	CcSEcCtD
Betamethasone—Hypotension—Carmustine—lymphatic system cancer	0.000795	0.00123	CcSEcCtD
Betamethasone—Oedema—Mitoxantrone—lymphatic system cancer	0.000791	0.00122	CcSEcCtD
Betamethasone—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000791	0.00122	CcSEcCtD
Betamethasone—Nausea—Fludarabine—lymphatic system cancer	0.00079	0.00122	CcSEcCtD
Betamethasone—Infection—Mitoxantrone—lymphatic system cancer	0.000786	0.00122	CcSEcCtD
Betamethasone—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000785	0.00122	CcSEcCtD
Betamethasone—Shock—Mitoxantrone—lymphatic system cancer	0.000778	0.0012	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000775	0.0012	CcSEcCtD
Betamethasone—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000775	0.0012	CcSEcCtD
Betamethasone—Urticaria—Bleomycin—lymphatic system cancer	0.000775	0.0012	CcSEcCtD
Betamethasone—Anorexia—Vincristine—lymphatic system cancer	0.000774	0.0012	CcSEcCtD
Betamethasone—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000772	0.00119	CcSEcCtD
Betamethasone—Body temperature increased—Bleomycin—lymphatic system cancer	0.000771	0.00119	CcSEcCtD
Betamethasone—Insomnia—Carmustine—lymphatic system cancer	0.00077	0.00119	CcSEcCtD
Betamethasone—Irritability—Methotrexate—lymphatic system cancer	0.000766	0.00118	CcSEcCtD
Betamethasone—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000765	0.00118	CcSEcCtD
Betamethasone—Paraesthesia—Carmustine—lymphatic system cancer	0.000764	0.00118	CcSEcCtD
Betamethasone—Mood swings—Methotrexate—lymphatic system cancer	0.00076	0.00118	CcSEcCtD
Betamethasone—Hypotension—Vincristine—lymphatic system cancer	0.000759	0.00117	CcSEcCtD
Betamethasone—Anorexia—Mitoxantrone—lymphatic system cancer	0.000754	0.00117	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00074	0.00115	CcSEcCtD
Betamethasone—Decreased appetite—Carmustine—lymphatic system cancer	0.00074	0.00114	CcSEcCtD
Betamethasone—Hypotension—Mitoxantrone—lymphatic system cancer	0.000739	0.00114	CcSEcCtD
Betamethasone—Insomnia—Vincristine—lymphatic system cancer	0.000735	0.00114	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000735	0.00114	CcSEcCtD
Betamethasone—Paraesthesia—Vincristine—lymphatic system cancer	0.000729	0.00113	CcSEcCtD
Betamethasone—Pain—Carmustine—lymphatic system cancer	0.000728	0.00113	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000721	0.00112	CcSEcCtD
Betamethasone—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00071	0.0011	CcSEcCtD
Betamethasone—Decreased appetite—Vincristine—lymphatic system cancer	0.000706	0.00109	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000701	0.00109	CcSEcCtD
Betamethasone—Feeling abnormal—Carmustine—lymphatic system cancer	0.000701	0.00109	CcSEcCtD
Betamethasone—Fatigue—Vincristine—lymphatic system cancer	0.0007	0.00108	CcSEcCtD
Betamethasone—Asthenia—Bleomycin—lymphatic system cancer	0.0007	0.00108	CcSEcCtD
Betamethasone—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000696	0.00108	CcSEcCtD
Betamethasone—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000696	0.00108	CcSEcCtD
Betamethasone—Pain—Vincristine—lymphatic system cancer	0.000695	0.00108	CcSEcCtD
Betamethasone—Pruritus—Bleomycin—lymphatic system cancer	0.00069	0.00107	CcSEcCtD
Betamethasone—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000688	0.00106	CcSEcCtD
Betamethasone—Fatigue—Mitoxantrone—lymphatic system cancer	0.000682	0.00106	CcSEcCtD
Betamethasone—Pain—Mitoxantrone—lymphatic system cancer	0.000677	0.00105	CcSEcCtD
Betamethasone—Abdominal pain—Carmustine—lymphatic system cancer	0.000673	0.00104	CcSEcCtD
Betamethasone—Body temperature increased—Carmustine—lymphatic system cancer	0.000673	0.00104	CcSEcCtD
Betamethasone—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000664	0.00103	CcSEcCtD
Betamethasone—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000652	0.00101	CcSEcCtD
Betamethasone—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000647	0.001	CcSEcCtD
Betamethasone—Abdominal pain—Vincristine—lymphatic system cancer	0.000642	0.000994	CcSEcCtD
Betamethasone—Body temperature increased—Vincristine—lymphatic system cancer	0.000642	0.000994	CcSEcCtD
Betamethasone—Urticaria—Mitoxantrone—lymphatic system cancer	0.000629	0.000973	CcSEcCtD
Betamethasone—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000625	0.000968	CcSEcCtD
Betamethasone—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000625	0.000968	CcSEcCtD
Betamethasone—Vomiting—Bleomycin—lymphatic system cancer	0.00062	0.000959	CcSEcCtD
Betamethasone—Rash—Bleomycin—lymphatic system cancer	0.000615	0.000951	CcSEcCtD
Betamethasone—Dermatitis—Bleomycin—lymphatic system cancer	0.000614	0.00095	CcSEcCtD
Betamethasone—Asthenia—Carmustine—lymphatic system cancer	0.000611	0.000945	CcSEcCtD
Betamethasone—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000601	0.00093	CcSEcCtD
Betamethasone—Asthenia—Vincristine—lymphatic system cancer	0.000583	0.000902	CcSEcCtD
Betamethasone—Diarrhoea—Carmustine—lymphatic system cancer	0.000582	0.000901	CcSEcCtD
Betamethasone—Nausea—Bleomycin—lymphatic system cancer	0.000579	0.000896	CcSEcCtD
Betamethasone—Asthenia—Mitoxantrone—lymphatic system cancer	0.000568	0.000878	CcSEcCtD
Betamethasone—Dizziness—Carmustine—lymphatic system cancer	0.000563	0.000871	CcSEcCtD
Betamethasone—Haemoglobin—Methotrexate—lymphatic system cancer	0.000558	0.000863	CcSEcCtD
Betamethasone—Diarrhoea—Vincristine—lymphatic system cancer	0.000556	0.00086	CcSEcCtD
Betamethasone—Haemorrhage—Methotrexate—lymphatic system cancer	0.000555	0.000859	CcSEcCtD
Betamethasone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000541	0.000838	CcSEcCtD
Betamethasone—Vomiting—Carmustine—lymphatic system cancer	0.000541	0.000837	CcSEcCtD
Betamethasone—Dizziness—Vincristine—lymphatic system cancer	0.000537	0.000831	CcSEcCtD
Betamethasone—Rash—Carmustine—lymphatic system cancer	0.000537	0.00083	CcSEcCtD
Betamethasone—Dermatitis—Carmustine—lymphatic system cancer	0.000536	0.00083	CcSEcCtD
Betamethasone—Visual impairment—Methotrexate—lymphatic system cancer	0.000535	0.000827	CcSEcCtD
Betamethasone—Headache—Carmustine—lymphatic system cancer	0.000533	0.000825	CcSEcCtD
Betamethasone—Eye disorder—Methotrexate—lymphatic system cancer	0.000519	0.000802	CcSEcCtD
Betamethasone—Vomiting—Vincristine—lymphatic system cancer	0.000517	0.000799	CcSEcCtD
Betamethasone—Rash—Vincristine—lymphatic system cancer	0.000512	0.000793	CcSEcCtD
Betamethasone—Dermatitis—Vincristine—lymphatic system cancer	0.000512	0.000792	CcSEcCtD
Betamethasone—Headache—Vincristine—lymphatic system cancer	0.000509	0.000788	CcSEcCtD
Betamethasone—Nausea—Carmustine—lymphatic system cancer	0.000506	0.000782	CcSEcCtD
Betamethasone—Angiopathy—Methotrexate—lymphatic system cancer	0.000503	0.000779	CcSEcCtD
Betamethasone—Vomiting—Mitoxantrone—lymphatic system cancer	0.000503	0.000778	CcSEcCtD
Betamethasone—Rash—Mitoxantrone—lymphatic system cancer	0.000499	0.000772	CcSEcCtD
Betamethasone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000498	0.000771	CcSEcCtD
Betamethasone—Headache—Mitoxantrone—lymphatic system cancer	0.000496	0.000767	CcSEcCtD
Betamethasone—Alopecia—Methotrexate—lymphatic system cancer	0.00049	0.000759	CcSEcCtD
Betamethasone—Erythema—Methotrexate—lymphatic system cancer	0.000483	0.000747	CcSEcCtD
Betamethasone—Nausea—Vincristine—lymphatic system cancer	0.000483	0.000747	CcSEcCtD
Betamethasone—Nausea—Mitoxantrone—lymphatic system cancer	0.00047	0.000727	CcSEcCtD
Betamethasone—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000448	0.000693	CcSEcCtD
Betamethasone—Malaise—Methotrexate—lymphatic system cancer	0.000436	0.000674	CcSEcCtD
Betamethasone—Vertigo—Methotrexate—lymphatic system cancer	0.000434	0.000671	CcSEcCtD
Betamethasone—Convulsion—Methotrexate—lymphatic system cancer	0.000418	0.000648	CcSEcCtD
Betamethasone—Myalgia—Methotrexate—lymphatic system cancer	0.000411	0.000636	CcSEcCtD
Betamethasone—Discomfort—Methotrexate—lymphatic system cancer	0.000406	0.000629	CcSEcCtD
Betamethasone—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000394	0.00061	CcSEcCtD
Betamethasone—Infection—Methotrexate—lymphatic system cancer	0.000392	0.000606	CcSEcCtD
Betamethasone—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000387	0.000598	CcSEcCtD
Betamethasone—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000386	0.000597	CcSEcCtD
Betamethasone—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000381	0.00059	CcSEcCtD
Betamethasone—Anorexia—Methotrexate—lymphatic system cancer	0.000376	0.000581	CcSEcCtD
Betamethasone—Hypotension—Methotrexate—lymphatic system cancer	0.000368	0.00057	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000359	0.000556	CcSEcCtD
Betamethasone—Insomnia—Methotrexate—lymphatic system cancer	0.000357	0.000552	CcSEcCtD
Betamethasone—Paraesthesia—Methotrexate—lymphatic system cancer	0.000354	0.000548	CcSEcCtD
Betamethasone—Dyspepsia—Methotrexate—lymphatic system cancer	0.000347	0.000537	CcSEcCtD
Betamethasone—Decreased appetite—Methotrexate—lymphatic system cancer	0.000343	0.00053	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00034	0.000527	CcSEcCtD
Betamethasone—Fatigue—Methotrexate—lymphatic system cancer	0.00034	0.000526	CcSEcCtD
Betamethasone—Pain—Methotrexate—lymphatic system cancer	0.000337	0.000522	CcSEcCtD
Betamethasone—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000325	0.000503	CcSEcCtD
Betamethasone—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000322	0.000499	CcSEcCtD
Betamethasone—Urticaria—Methotrexate—lymphatic system cancer	0.000313	0.000485	CcSEcCtD
Betamethasone—Abdominal pain—Methotrexate—lymphatic system cancer	0.000312	0.000482	CcSEcCtD
Betamethasone—Body temperature increased—Methotrexate—lymphatic system cancer	0.000312	0.000482	CcSEcCtD
Betamethasone—Asthenia—Methotrexate—lymphatic system cancer	0.000283	0.000438	CcSEcCtD
Betamethasone—Pruritus—Methotrexate—lymphatic system cancer	0.000279	0.000432	CcSEcCtD
Betamethasone—Diarrhoea—Methotrexate—lymphatic system cancer	0.00027	0.000417	CcSEcCtD
Betamethasone—Dizziness—Methotrexate—lymphatic system cancer	0.000261	0.000403	CcSEcCtD
Betamethasone—Vomiting—Methotrexate—lymphatic system cancer	0.000251	0.000388	CcSEcCtD
Betamethasone—Rash—Methotrexate—lymphatic system cancer	0.000249	0.000385	CcSEcCtD
Betamethasone—Dermatitis—Methotrexate—lymphatic system cancer	0.000248	0.000384	CcSEcCtD
Betamethasone—Headache—Methotrexate—lymphatic system cancer	0.000247	0.000382	CcSEcCtD
Betamethasone—Nausea—Methotrexate—lymphatic system cancer	0.000234	0.000362	CcSEcCtD
